Novartis | NVS - Pre Tax Profit


Novartis reported $3.84B in Pre-Tax Profit for its fiscal quarter ending in March of 2026.





Pre Tax Profit Change Date
AbbVie USD 7.61B 2.04B Jun/2026
Amgen USD 2.08B 570M Mar/2026
AstraZeneca USD 4.81B 894M Jun/2026
Bausch Health Companies USD 348M 1.7B Jun/2026
Biogen USD 647.3M 269.6M Jun/2026
Bristol-Myers Squibb USD 4.99B 1.75B Jun/2026
Canopy Growth CAD -157.96M 95.71M Mar/2026
Corcept Therapeutics USD -44.72M 54.62M Mar/2026
Drreddys Laboratories INR 2B 13.43B Mar/2026
Eli Lilly USD 8.85B 583.8M Mar/2026
Gilead Sciences USD -7.53B 10.11B Jun/2026
GlaxoSmithKline GBP 2.68B 532M Jun/2026
Glaxosmithkline GBP 2.14B 312M Mar/2026
J&J USD 8.66B 839M Jun/2026
Merck USD -3.53B 6.95B Mar/2026
Novartis USD 4.27B 430M Jun/2026
Novartis USD 3.84B 1.33B Mar/2026
Pacira USD 5M 4.43M Mar/2026
Perrigo USD 105.4M 513.9M Jun/2026
Pfizer USD -653M 5.84B Jun/2026
Phibro Animal Health USD 38.62M 1.26M Dec/2025
Prestige Brands USD 64.77M 2.96M Mar/2026
Roche Holding CHF 11.17B 6.38B Jun/2026
Sanofi EUR 837M 1.17B Jun/2026
Sanofi EUR 2B 3.16B Mar/2026
Supernus Pharmaceuticals USD -57.65M 51.7M Jun/2026
Zoetis USD 758M 3M Mar/2026